Company

Eli Lilly Q3 Revenue Soars 39% to USD 24.4 Billion as Mounjaro Sales Jump 65% and China Revenue Climbs 69%; Full‑Year Guidance Raised to USD 91–92 Billion
Eli LillyFinanical Reports

Eli Lilly Q3 Revenue Soars 39% to USD 24.4 Billion as Mounjaro Sales Jump 65% and China Revenue Climbs 69%; Full‑Year Guidance Raised to USD 91–92 Billion

Eli Lilly and Company (NYSE: LLY) reported third‑quarter 2026 worldwide revenue of USD 24.4 billion, up 39% year‑on‑year, driven by strong demand for its diabetes and obesity treatments Mounjaro (tirzepatide)…

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

Wanbangde Receives FDA Feedback Endorsing Pivotal Phase III Path for WP205 Mecobalamin Injection in ALS

Wanbangde Receives FDA Feedback Endorsing Pivotal Phase III Path for WP205 Mecobalamin Injection in ALS

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Shanghai MicroPort EP MedTech's IceMagic Catheter Receives EU MDR Certification
CVDMicroport EP Medtech

Shanghai MicroPort EP MedTech’s IceMagic Catheter Receives EU MDR Certification

CTTQ Doses First Patient in China for TQB6411 Phase I Clinical Trial
CancerChia Tai Tianqing Pharmaceutical

CTTQ Doses First Patient in China for TQB6411 Phase I Clinical Trial

FDA-Approved Smile System Launches in Lecheng for ADHD Treatment
Boao Lecheng pilot zoneNu Eyne

FDA-Approved Smile System Launches in Lecheng for ADHD Treatment

Grand Pharma’s TLX591 Granted NMPA Approval for Phase III Prostate Cancer Trial
ASX: TLXCancer

Grand Pharma’s TLX591 Granted NMPA Approval for Phase III Prostate Cancer Trial

Show More